Collaborations Exelixis has a history of productive drug discovery, and we have partnered multiple compounds and programs with leading pharmaceutical and biopharmaceutical companies, including Bristol-Myers Squibb Company, Genentech (a member of the Roche Group), Sanofi, Merck (known as MSD outside of the United States and Canada), and Daiichi-Sankyo Company Limited. These collaborations cover a variety of compounds and programs with potential for use in the treatment of cancer, inflammation, and cardiovascular and metabolic diseases. About Us COMETRIQ® Pipeline Clinical Trials Medical Information Investors & Media Responsibility Careers About Us Management Board of Directors Collaborations Locations Contact Us © Exelixis, Inc. 2015 Website design: Hane Chow, Inc. Privacy Terms of Use

Management Our leadership team is united by an unwavering commitment to creating value through the development of innovative new therapies to improve the treatment of cancer. Bringing together years of industry experience, our dedicated team shares the same vision to create therapies that make a meaningful difference in the lives of patients. Michael M. Morrissey, Ph.D. President and Chief Executive Officer Jeffrey J. Hessekiel, J.D. Executive Vice President and General Counsel Peter Lamb, Ph.D. Executive Vice President, Discovery Research and Chief Scientific Officer Gisela M. Schwab, M.D. Executive Vice President and Chief Medical Officer Christopher J. Senner Executive Vice President and Chief Financial Officer About Us COMETRIQ® Pipeline Clinical Trials Medical Information Investors & Media Responsibility Careers About Us Management Michael M. Morrissey Jeffrey J. Hessekiel Peter Lamb Gisela M. Schwab Christopher J. Senner Board of Directors Collaborations Locations Contact Us © Exelixis, Inc. 2015 Website design: Hane Chow, Inc. Privacy Terms of Use